---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-028352"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2024-07-18T23:59:59+00:00"
generated_at: "2026-05-31T19:42:21.665024+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Evofem acquires Solosec from Lupin for up to $84M in contingent consideration

## Summary
- Evofem (OTCQB: EVFM) acquired Solosec (secnidazole) from Lupin Inc.; deal closed July 14, 2024.
- Potential total consideration up to $84 million based on future contingent milestones; plus assumption of certain liabilities.
- Solosec is an FDA-approved single-dose oral treatment for bacterial vaginosis and trichomoniasis.
- Acquisition complements Evofem's women's health portfolio, which includes Phexxi; Evofem also in merger with Aditxt (ADTX).

## SEC filing metadata
- accession: 0001493152-24-028352
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2024-07-18T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000149315224028352/0001493152-24-028352-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000149315224028352/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-028352
- JSON: https://secwatch.observer/filing/0001493152-24-028352.json
- Plain text: https://secwatch.observer/filing/0001493152-24-028352.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.